| Combines trifluridine (which inhibits cell proliferation by interfering with DNA synthesis) with tipiracil (which increases systemic exposure to trifluridine) |
| Prolongs OS, PFS and time to deterioration of ECOG performance status in comparison to placebo |
| Does not adversely affect health-related quality of life |
| Manageable safety and tolerability profile |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.